Phase 2 Lymphoma Trial, Recruiting

Written by an AI model from ClinicalTrials.gov eligibility criteria and checked on a sample basis. Please confirm against the original criteria.

Who might be able to join this trial:

• Adults aged 18 or older.
• People who have been diagnosed with a high-grade brain tumour called a glioma — this includes glioblastoma (IDH-wild type), Grade 3 or 4 IDH-mutant astrocytoma, Grade 3 oligodendroglioma, a previously lower-grade astrocytoma or oligodendroglioma that is now suspected to have come back at a higher grade, or another type of high-grade glioma.
• People whose treatment plan already includes surgery to remove the tumour as part of their standard care.
• People whose scans show the tumour has grown or returned (with or without a tissue sample confirming this).
• People who have measurable tumour visible on scans.
• People whose general health and ability to carry out daily activities meets a certain minimum level, as measured by standard medical scoring tools (confirm with trial site).
• People whose blood test results from within the past 15 days show healthy enough levels of red blood cells, white blood cells, and platelets.
• People whose blood test results from within the past 15 days show the liver is functioning within an acceptable range.
• People whose kidney function, measured by a standard calculation from recent blood tests, meets the required minimum level.
• People who are not pregnant, confirmed by a negative pregnancy test taken within 7 days before registering (applies to people who could become pregnant).
• People who are willing to sign a consent form for this study.
• People who are willing to consent to having tissue, fluid, and/or blood samples stored in a research collection.
• People who are able to complete study forms, either on their own or with help.
• People who are willing to return to the enrolling hospital for follow-up visits during the active part of the study.

Who may not be able to join:

• People who are pregnant, breastfeeding, or people who could become pregnant or father a child and are not willing to use adequate contraception — because the effects of the study drug on an unborn baby or newborn are not yet known.
• People with a serious uncontrolled illness that the study doctor considers would make participation unsafe or interfere with assessing the treatment, including active infections requiring treatment, a current or past history of non-infectious lung inflammation that needed steroids, an active autoimmune disease that required systemic treatment (other than routine hormone or steroid replacement) within the past 2 years, symptomatic heart failure, unstable chest pain, or psychiatric or social conditions that would make it difficult to follow the study requirements.
• People who currently have both active Hepatitis B and active Hepatitis C infections at the same time — though exceptions may apply for people who have completed antiviral treatment and whose virus levels are undetectable (confirm with trial site).
• People with other serious ongoing illnesses that the study doctor considers would make participation unsafe or interfere with properly evaluating the treatment.
• People who have had a heart attack within the past 6 months, or who have heart failure requiring ongoing treatment for dangerous heart rhythm problems.
• People who have had an active autoimmune disease requiring systemic treatment (other than routine replacement therapy) within the past year.
• People who have previously received an allogeneic stem cell transplant (a transplant using donor stem cells).
• People who are currently taking another experimental treatment intended to treat their condition.
• People who are unable to swallow the liquid form of one of the study drugs, or who may not be able to absorb it properly — for example, due to persistent vomiting or previous stomach or bowel surgery.
• People who have a known allergy or sensitivity to either of the study drugs (DFMO or retifanlimab).
• People for whom an MRI scan or the contrast dye used during MRI (gadolinium) is not safe or suitable.

Important: Always verify eligibility with the trial site directly before applying.